



Editor

Tracy Crooks

Reckitt Benckiser Healthcare International Ltd
email: tracy.crooks@reckittbenckiser.com

Advisory Panel

Elliot Brown

Managing Director, Elliot Brown Consulting Ltd

David Cousins

Head of Safe Medication Practice, National Patient Safety Agency

Alison Ewing

Clinical Director of Pharmacy, Royal Liverpool and Broadgreen University Hospitals NHS Trust

Graeme Ladds

Director, PharSafer Associates Ltd.

Sunayana Shah

Scientific & Medical Affairs Manager at the Proprietary Association of Great Britain (PAGB)

Publisher

Joe Ridge

Design & Production

Sarah Beale

Subscriptions

Jill Monk

email: subs@euromedcommunications.com

Published by Euromed Communications Ltd
Passfield Business Centre, Passfield, Liphook,
Hampshire GU30 7SB, UK
Tel: +44 (0)1428 752222
Fax: +44 (0)1428 752223

email: info@euromedcommunications.com
www.euromedcommunications.com

Euromed Communications Ltd also publish
Clinical Research Manual; Paediatric Clinical
Research Manual, Medical Devices Manual and
Compendium of Quality of Life Instruments

Copyright: No part of this journal may be reproduced without written permission from the Publishers. The comments of the contributors are their own and are not necessarily endorsed by the Publisher, Editor or Advisory Panel. Accordingly the Publisher, Editor or Advisory Panel accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement. The Editor's decision is final and no correspondence will be entered into. The utmost care has been taken to ensure accuracy of detail, but the publishers cannot accept responsibility for errors or omissions.

© 2011 Euromed Communications Ltd

ISSN 1752-6752

Contents

August 2011 • Volume 5 Number 3

3 Editorial comment

Tracy Crooks

4 Risks of off-label medicines in children

One fifth of all spontaneous ADRs reported in Danish children were associated with off-label prescribing and 60% were serious.
Lise Aagaard and Ebba Holme Hansen

8 Electronic submission of ADRs

The Yellow Card scheme for hospital medical information centres has been expanded for use by the pharma industry to enable it to transfer data electronically.
Keith Brown and Steve Moss

11 Preparing for Development Safety Update Reports: some implications for pharmaceutical companies

From September 2011 companies sponsoring clinical trials in the EU should submit Development Safety Update Reports (DSURs). This article summarises the guidelines and implications.
Dr Elliot Brown

17 UK Inspection findings for 2010/2011

The latest MHRA Pharmacovigilance Inspection Reports for 2011/2011 show a continuation of the steady decrease in the number of fundings per inspection.
Joe Ridge

20 Detecting drug interactions from adverse-event reports

Data mining of the FDA's Adverse Events Reporting System has proved to be a useful method of detecting potentially important clinical signals.
Ros Manning